Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen

  • Authors:
    • Marcela Gallardo
    • Gloria M. Calaf
  • View Affiliations

  • Published online on: April 7, 2016     https://doi.org/10.3892/ijo.2016.3477
  • Pages: 2534-2542
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is a major cause of global mortality in women. Curcumin exerts anti-proliferative, anti-migratory and apoptotic effects. The aim of this study was to evaluate gene expression involved in epithelial-mesenchymal transition (EMT). An in vitro model was developed with the MCF-10F immortalized breast epithelial cell line exposed to low radiation doses of high LET (linear energy transfer) α-particles (150 keV/µm) and cultured in the presence of 17β-estradiol (estrogen). The following cell lines were used: i) MCF-10F, normal; ii) Alpha5, pre-tumorigenic, and iii) Tumor2 derived from Alpha5 injected into the nude mice. Our previous results have shown that Alpha5 and Tumor2 increased cell proliferation, anchorage independency, invasive capabilities and tumor formation in nude mice in comparison to control. Results indicated that curcumin decreased expression of EMT-related genes in Tumor2 cell line when compared to its counterpart as E-cadherin, N-cadherin, ZEB2, Twist1, Slug, Axl, vimentin, STAT-3, fibronectin; and genes p53 and caveolin-1, as well as apoptotic genes caspase-3, caspase-8, and others such as cyclin D1 and NFκB. All these changes induced a decrease in migratory and invasive capabilities of such a cell line. Thus, it seems that curcumin may impinge upon apoptosis and metastatic properties of the malignant cells exerting antitumor activity in breast cancer cells transformed by low doses of α-particles and estrogen in vitro.

Introduction

Breast cancer is the most frequent malignancy diagnosed in women in the western world. Oxidative stress is one of the important pathogenic factors of cancer development (1). Both in vitro and in vivo studies have shown that curcumin and its analogs target critical genes associated with angiogenesis, apoptosis, cell cycle, and metastasis (1). Among the antioxidants, curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; (diferuloylmethane) is a dietary natural yellow pigment derived from the rhizome of the turmeric herb known as Curcuma longa (Zingiberaceae) originating from India and South Asia. It is a polyphenol derived from several curcumin species, commonly known as turmeric which has been shown to inhibit carcinogen activation, modulate cell survival and apoptosis, with anti-invasive and anti-metastatic effects on breast, lung, colon and prostate cancer (1).

Epidemiological and experimental data demonstrated the efficacy of curcumin in chemoprevention and reversing chemoresistance of tumors of certain cancers. It possesses anti-proliferative and anti-carcinogenic potential (2,3). Curcumin interferes with multiple genes that promote carcinogenesis. It is a pleiotropic molecule with anti-proliferative, antioxidant and chemopreventive properties. Alteration of gene expressions involved in key signaling pathways render this model an important tool for monitoring effects of natural dietary compounds in breast carcinogenesis (2).

One important concept of epithelial-mesenchymal transition (EMT), which has been recognized for several decades as a fundamental process of embryogenesis, is currently considered a pivotal event in the initial step of the metastatic cascade that allows cells to acquire migratory, invasive and stem-like properties (4).

During EMT of cancer cells in situ, epithelial cell layers lose polarity together with cell-to-cell contacts and then undergo a dramatic remodeling of the cytoskeleton. Changes in gene expression that promote cell-to-cell contact, such as E-cadherin and γ-catenin, may be lost and the cells may acquire mesenchymal characteristics such as changes at N-cadherin, vimentin, fibronectin levels resulting in an enhanced ability for cell migration and invasion (5). Cadherins are glycoproteins responsible for homotypic and calcium-dependent cell-cell adhesion (6). E-cadherin is a membrane glycoprotein that plays an essential role in maintaining the integrity of cell-to-cell adhesion, which is significantly associated with tumor invasiveness and metastatic dissemination (7). Dysfunction or loss of E-cadherin is associated with an increased tendency for tumor metastasis (8). In addition, degradation of extracellular matrix and basement membranes by the tumor cells is a critical step and occurs at several stages of the metastatic cascade (9,10). N-cadherin (cadherin-2 or CDH-2) is a mesenchymal cadherin overexpressed in many cancers and associated with cancer cell migration and FGF receptor signaling in breast cancer metastasis (11). β-catenin is a 92 kDa protein that plays a role in both cell adhesion and intracellular signaling (12) as the classical cadherins which play fundamental roles in the development of multicellular organisms (13).

Smad interacting protein 1 (SIP1; also known as ZEB2, for zinc finger E-box-binding protein 2 and ZFHX1B) belongs to the δEF-1 or ZEB protein family (14) and are transcriptional factors characterized by containing a homeo domain flanked by two separated zinc finger clusters (15). It is expressed in various types of human tumors, such as breast cancer, gastric cancer and ovarian cancer (15). ZEB2 is a potent repressor of E-cadherin through its direct binding to the E-cadherin promoter and a key player in tumor cell invasion and metastasis (16,17).

Twist1 induces EMT and extracellular matrix degradation in tumor progression (1820). Slug is a member of the SNAI family of C2H2-zinc finger family of transcriptional repressors (2123). It is involved in the EMT during development (22), acts as an inhibitor of apoptosis (24), and causes tubulogenesis during breast and kidney developments (21,22). AXL is a member of the TAM (Tyro3, Axl, Mer) family of receptor tyrosine kinases (RTK), originally identified as a transforming gene in cells of chronic myelogenous leukemia patients. It is activated through several mechanisms, including binding of its ligand, growth arrest specific 6 (Gas6), and extracellular domain-mediated dimerization or crosstalk with HER2/neu (2527). Vimentin belongs to intermediate filaments that with microfilaments and microtubules are the major cytoskeletal elements of the cell (28,29).

STAT-3, a versatile member of the family known as signal transducers and activators of transcription (STAT) mediates the axial responses of cytokines. STAT-3 is involved in normal cellular responses, as well as oncogenesis (30). Fibronectin is a component of the extracellular matrix and exerts multiple effects in vitro and in vivo including stimulation of cell proliferation, migration, differentiation and survival (3134). It affects cell behavior through activation of various cell surface receptors most notably integrins (35). Fibronectin is required for the development of fibrillar structures (36) and for the storage and activation of various growth factors (37).

The p53 gene is known as the guardian of the genome (38). A major biological function of p53 is to respond to stress signals and activate the transcription of downstream target genes involved in important cellular mechanisms like cell cycle control, DNA repair and apoptosis. Caveolin is a specialized lipid raft on the plasma membrane found in mesenchymal cells. The caveolin family consists of three members, caveolin-1 (Cav-1), caveolin-2 and caveolin-3. Cav-1 is widely expressed in various tissues and plays an essential role in a number of human diseases including cancer (39).

Apoptosis is genetic death program (40). The balance between pro- and anti-apoptotic signals maintain biological homeostasis and its imbalance is related to malignant transformation (40). The central component of the apoptotic machinery is the family of caspases (41,42). The members of the caspase family can be divided into two groups: i) upstream initiator caspases, such as caspase-8 and ii) downstream effector caspases, such as caspase-3 (43,44).

Cyclins, cyclin-dependent kinases (cdks) have been identified as regulatory subunits (cyclins) and catalytic subunits (cdks) of cell cycle-regulated kinases involved in the control of mitosis. It is involved in regulating the G1 to S transition (45,46). Abnormalities involving cyclin D1 may deregulate control of the G1-S transition and, therefore, contribute to genomic instability and tumor development (45,46). Cyclin D1 along with its binding partners CDK 4/6 partially mediate G1 to S-phase transition of the cell cycle through phosphorylation and inactivation of retinoblastoma (Rb) protein with subsequent release of E2F transcription factors (4749). It is believed that the oncogenic properties of cyclin D1 depend to a large extent on its ability to activate cyclin-dependent kinases 4 or 6 (Cdk4/6) (50,51).

Nuclear Factor κB (NFκB) is a complex of transcription factors that function in the development of acquired resistance to several other targeted agents (52). NFκB signaling has two major pathways, one is the canonical pathway that mainly modulates cell proliferation, inflammation or anti-apoptosis, and the other one is the non-canonical pathway that mainly controls lymphogenesis (53).

To gain insights into the effects of curcumin on breast carcinogenesis an established in vitro experimental breast cancer model (Alpha model) (54) was used. It was developed with the immortalized human breast epithelial cell line, MCF-10F (55) that was exposed to low doses of high LET (linear energy transfer) α-particles (150 keV/μm) of radiation, values comparable to α-particles emitted by radon progeny, and subsequently cultured in presence or absence of 17β-estradiol (estrogen). MCF-10F was exposed to low doses of high LET α-particles (150 keV/microm) and subsequently cultured in the presence or absence of 17beta-estradiol (E) for periods of up to 10 months post-irradiation. MCF-10F cells irradiated with either a single 60 cGy dose or 60/60 cGy doses of α-particles showed gradual phenotypic changes including altered morphology, increase in cell proliferation relative to the control, anchorage-independent growth and invasive capability before becoming tumorigenic in nude mice. In addition, these cells present all the characteristics of breast epithelium in their ultra structural features (5658). However, only those MCF-10F cells treated with a 60 cGy dose of α-particles followed by estrogen treatment and exposed to a second dose of 60 cGy dose of α-particles followed by estrogen (60 cGy + E/60 cGy + E), named Alpha5 became tumorigenic in both SCID and nude mice (54). Tumor2 developed from Alpha5 injected in the athymic mice. The aim of this work was to evaluate the effect of curcumin on epithelial mesenchymal transition and other related genes in breast cancer cells transformed by low doses of α-particles and estrogen.

Materials and methods

Breast cancer cell lines

The spontaneously immortalized breast epithelial cell line, MCF-10F cells was grown in DMEM/F-12 (1:1) medium supplemented with antibiotics 100 U/ml penicillin, 100 μg/ml streptomycin, 2.5 μg/ml amphotericin B (all from Life Technologies, Grand Island, NY, USA) and 10 μg/ml and 5% equine serum (Biofluids, Rockville, MD, USA), 0.5 μg/ml hydrocortisone (Sigma, St. Louis, MO, USA) and 0.02 μg/ml epidermal growth factor (Collaborative Research, Bedford, MA, USA). An in vitro experimental breast cancer model developed by exposure of the immortalized human breast epithelial cell line was used. MCF-10F was exposed to low doses of high LET (linear energy transfer) α-particles radiation (150 keV/μm) and subsequent growth in the presence or absence of 17β-estradiol at 10−8 M (E or Estrogen) (Sigma-Aldrich, St. Louis, MO, USA). The following cell line consisted of human breast epithelial cells in different stages of transformation: i) a control cell line, MCF-10F; ii) Alpha5 and iii) Tumor2 (54).

RNA extraction and cDNA synthesis

RNA from cells were obtained using TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA) following to the manufacturer's protocol. RNA (2 μg) were reverse-transcribed to cDNA with kit High capacity cDNA Reverse Transcription (Applied Biosystems, Carlsbad, CA, USA).

RT-qPCR

Synthesized cDNA (2 μl) was mixed in 20 μl qPCR reaction containing SYBR Green PCR Master Mix (Agilent, La Jolla, CA, USA) and 5 μM of primers for the target genes such as E-cadherin, N-cadherin, β-catenin, ZEB2, Twist, Slug, Axl, vimentin, STAT-3, fibronectin, p53, caveolin-1, caspase-3, caspase-8, cyclin D1 and NFκB. Table I shows the primers to develop cDNA probes. CFX 96 Touch Real-time PCR Detection Systems (Bio-Rad Laboratories, Hercules, CA, USA) was used to perform the reaction with the following conditions: 95°C for 10 min and 40 cycles of a 2-step program of 95°C for 10 sec and 61°C for 45 sec. Reactions were performed in triplicate. Threshold cycle (Ct) was obtained using Bio-Rad CFX Manager 2.1 software. Gene expression was normalized using β-actin. Relative expression was always normalized to the average breast cells and its counterparts.

Table I

Primers for genes selected to develop cDNA probes.

Table I

Primers for genes selected to develop cDNA probes.

Gene nameProduct length (bp)aPrimer sequenceb
E-cadherin93F: AGTGGGCACAGATGGTGTGA
R: TAGGTGGAGTCCCAGGCGTA
N-cadherin67F: TCG ATT GGT TTG ACC ACG G
R: GAC GGT TCG CCA TCC AGA C
β-catenin94F: GCAGAGTGCTGAAGGTGCTA
R: TCTGTCAGGTGAAGTCCTAAAGC
ZEB2128F: CAAGAGGCGCAAACAAGC
R: GGTTGGCAATACCGTCATCC
Twist1118F: TCCGCGTCCCACTAGCA
R: AGTTATCCAGCTCCAGAGTCTCTAGAC
Slug72F: GACCCTGGTTGCTTCAAGGA
R: TGTTGCAGTGAGGGCAAGAA
AXL121F: GTTTGGAGCTGTGATGGAAGGC
R: CGCTTCACTCAGGAAATCCTCC
Vimentin117F: TGTCCAAATCGATGTGGATGTTTC
R: TTGTACCATTCTTCTGCCTCCTG
STAT-3163F: GGTTGGACATGATGCACACTAT
R: AGGGCAGACTCAAGTTTATCAG
Fibronectin105F: GGAGGAAGCCGAGGTTTTAAC
R: ACGCTCATAAGTGTCACCCA
mp53128F: CCTCAGCATCTTATCCGAGTGG
R: TGGATGGTGGTACAGTCAGAGC
Caveolin-179F: AACGATGACGTGGTCAAGATTG
R: TCCAAATGCCGTCAAAACTGT
Caspase-3192F: CAGAACTGGACTGTGGCATTG
R: GCTTGTCGGCATACTGTTTCA
Caspase-8128F: CATCCAGTCACTTTGCCAGA
R: GCATCTGTTTCCCCATGTTT
Cyclin D160F: GTGGCCTCTAAGATGAAGGA
R: GGTGTAGATGCACAGCTTCT
NFκB114F: ATCTGCCGAGTGAACCGAAACT
R: CCAGCCTGGTCCCGTGAAA

a Length of cDNA product amplified by gene-specific RT-qPCR analysis.

b PCR primer sequences used to generate a product of the indicated size, listed in 5′ to 3′ orientation; F, forward; R, reverse.

Cell migration and invasion assays

Migration and invasiveness were performed using modified Boyden's chambers (Corning, Inc., Corning, NY, USA) constructed with multiwell cell culture plates and cell culture inserts. The upper chambers of Transwells with 8-μm membrane pores were pre-coated with 60 μl Matrigel matrix gel (BD Biosciences) at least 1 h before seeding of the tested cells (54). A total of 3×105 in 100 μl of medium without fetal bovine serum was added into the upper chambers and 600 μl of medium with 10% FBS was placed to lower chambers as chemoattractant. Cells were cultured for 48 h following treatment. Curcumin (30 μM) was added to the cell culture. Normal culture medium was added at the bottom chamber to induce the cancer cell lines. Cells which were pretreated were seeded in the top chamber. The matrigel invasion chamber was incubated for 16 h in a humidified tissue culture incubator. Then, the upper chambers were removed from lower chambers and then wiped using cotton swabs. The invaded and migrated cells were fixed using 100% methanol at room temperature for 15 min, visualized and quantified using DAPI. Three fields of each chamber were photographed (x40 magnification). This experiment was independently repeated at least twice.

Statistical analysis

Numerical data were expressed as the average ± standard error of the mean (SEM). Comparison between treated groups and controls was carried out by ANOVA and Dunnet's test. A P<0.05 was considered to be significant.

Results

Curcumin inhibited the expression of markers of EMT such as E-cadherin, N-cadherin, β-catenin and ZEB2 in breast cancer cells (Fig. 1A–D). Results in Fig. 1A–D show a decrease in E-cadherin (Fig. 1A), N-caherin (Fig. 1B), β-catenin (Fig. 1C), and ZEB2 (Fig. 1D) gene expression in MCF-10F and Tumor2 (P<0.01) in comparison with its counterparts. However, there was no difference in Alpha5 cell line. Results in Fig. 2A–D show a decrease in other EMT-related genes Twist (Fig. 2A), Slug (Fig. 2B), Axl (Fig. 2C), and vimentin (Fig. 2D) gene expression in MCF-10F and Tumor2. However, there was no difference in Alpha5 cell line.

Curcumin induced a decrease in gene expression as shown in Figs. 3 and 4A–D for STAT-3 (Fig. 3A), fibronectin (Fig. 3B), mp53 (Fig. 3C), and Cav1 (Fig. 3D), caspase-8 (Fig. 4A), caspase-3 (Fig. 4B), cyclin D1 (Fig. 4C) and NFκB (Fig. 4D) in the malignant and tumorigenic cell line Tumor2 (P<0.01) in comparison with its counterpart. However, there was no difference in Alpha5 cell line in comparison with its counterpart. Since EMT is associated with cellular progression we studied the effect on migration and invasion of breast cancer cells. Curcumin decreased the number of migratory and invasive cells significantly (P<00.5) compared to the untreated cells as can be observed in Fig. 5.

Discussion

Accumulating evidences suggest that curcumin has a diverse range of molecular targets, supporting the concept that it acts upon numerous biochemical and molecular cascades. Despite our increasing knowledge on this interesting substance there still remain many unknown effects that deserve intense investigation. The multi-targeting of curcumin comes from its structure, chemistry and influence on multiple signaling molecules as well as its ability to bind directly to carrier proteins that improves its solubility and bioavailability. It binds to DNA and RNA. Both in vitro and in vivo studies have shown that curcumin and its analogs target critical genes associated with angiogenesis, apoptosis, cell cycle, and metastasis.

The MCF-10F is unique in the sense that it retains all the characteristics of normal breast epithelium in vitro including dome formation in confluent cultures, three-dimensional growth in collagen gel (55), dependence upon hormones and growth factors for growth in vitro, lack of anchorage-independence or invasive capabilities and non-tumorigenic in the nude or SCID mice (54). It was previously shown (59,60) that among all the various transformed human breast cell lines only Alpha5 cell line and Tumor2 increased cell proliferation, adhesion, presented anchorage-independency, invasive capabilities and tumor formation in nude mice. These cell lines were also positive for estrogen receptor, progesterone receptor and HER, c-Ha-ras and Rho-A gene and protein expression.

EMT is associated with enhanced cellular progression. Curcumin inhibited EMT gene expression in breast cancer cells as E-cadherin, N-cadherin, β-catenin and ZEB2 in Tumor2 in comparison with its counterparts. Curcumin also inhibited Twist1, Slug, Axl and vimentin gene expression in the same cell line. It is known that Twist1 promotes stationary epithelial cells to lose cell-cell junctions and gain migratory and invasive capacities (61); Slug acts as an inhibitor of apoptosis (24) and Axl is overexpressed in a wide variety of human cancers with significant correlation with tumor stage in breast cancer patients playing an important role in cancer progression and metastases (6264). Curcumin decreased STAT-3 and fibronectin gene expression in Tumor2 in comparison to its counterpart. It is known that STAT-3 mediates the axial responses of cytokines involved in normal cellular responses and oncogenesis (30).

The antioxidant inhibited Cav-1 gene expression of malignant and tumorigenic cell line Tumor2. It has been reported that inhibition of the tumor promoter Cav-1 expression in Hca-F cells prevents EMT formation by increasing stabilization of Cav-1 with β-catenin (65,66). Curcumin induced tumor cell apoptosis since it decreased caspase-3, caspase-8 and cyclin D1 expression in Tumor2 in comparison to its control. Abnormalities involving cyclin D1 may alter G1-S transition and contribute to genomic instability and tumor development (45,46). The ability of curcumin to induce apoptosis in tumor cells and/or potentiate apoptosis induction by classical chemotherapeutic drugs, support its potential in anticancer therapies (67,68). This substance also inhibited the mp53 gene expression of malignant and tumorigenic cell line Tumor2 in comparison to its control. Of note, curcumin has been found to inhibit proliferation of normal, non-selectively, as well as malignant cells, although its apoptogenic effect is more profound in malignant cells since it selectively induced apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner (69,70). The possibility that p53-mediated apoptosis may be associated with the activation of caspase-3 and caspase-8 is suggested by the ability of p53 to activate both the extrinsic and intrinsic apoptotic pathways (71). It has been reported that p53 activates effector caspases by possibly inducing the release of mitochondrial cytochrome-c, including caspase-3, and caspase-8 and through the apoptotic effector machinery engaged by p53 (72,73). It has been reported that p53 enhances cancer cell apoptosis and prevents cell replication by stopping the cell cycle at G1 or interphase (74).

Curcumin induced a reduction of tumor cell invasion and metastasis along with apoptosis. The motile phenotypes of cells treated with curcumin were evaluated by migration and invasion assay. After treatment with curcumin the number of migratory and invasive cells decreased significantly compared to the untreated cells. Curcumin has been reported to inhibit cell proliferation and promote accumulation of cells in the G2/M phase of the cell cycle (75).

Thus, the mechanism of apoptosis induced by curcumin seems to be through reduction of tumor cell invasion and metastasis by NFκB. The authors (76) showed that NFκB, a transcription factor in the cell was altered by curcumin. Curcumin plays an important role in the inhibition of EMT in breast cancer cells through the downregulation of NFκB-Snail activity (77). These data provide a new perspective of the anti-invasive mechanism of curcumin, indicating that the effect is partly due to its ability to intervene in the EMT process (77). The inhibition of human breast cancer cell growth by curcumin is mediated via certain signaling cascades including the modulation of the NFκB signaling pathway.

Several studies in vitro and first clinical investigations confirm the antitumor effects of curcumin, either as an isolated chemoprevention substance or in combination with chemotherapeutic agents as supportive measure reducing pharmaceutical resistance of tumor cells to certain chemotherapeutics. The ability of curcumin to induce apoptosis in tumor cells by a classical chemotherapeutic drug, or an antioxidant such as curcumin supports its potential in anticancer therapies. Despite our increasing knowledge on this interesting substance there still remain many unknown effects that deserve intense investigation. These studies reveal the inhibitory effect of curcumin with emphasis on multi-targeted biological and molecular effects in a breast cancer model. Thus, it seems that curcumin may impinge upon several processes including apoptosis and metastatic properties of the malignant cells exerting antitumor activity in breast cancer cells transformed by low doses of α-particles and estrogen in vitro.

Acknowledgements

The technical support of Guiliana Rojas, Georgina Vargas Marchant and Leodán A. Crispin and helpful suggestions given by Richard Ponce-Cusi are greatly appreciated. This study was supported by Grant support FONDECYT #1120006 (G.M.C.) and MINEDUC-UTA (G.M.C.).

References

1 

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, et al: Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. J Nutr. 130(Suppl): 467S–471S. 2000.PubMed/NCBI

2 

Khar A, Ali AM, Pardhasaradhi BV, Varalakshmi CH, Anjum R and Kumari AL: Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: Role of reactive oxygen intermediates. Cell Stress Chaperones. 6:368–376. 2001. View Article : Google Scholar

3 

Ramachandran C, Rodriguez S, Ramachandran R, Raveendran Nair PK, Fonseca H, Khatib Z, Escalon E and Melnick SJ: Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res. 25:3293–3302. 2005.PubMed/NCBI

4 

Cowin P and Welch DR: Breast cancer progression: Controversies and consensus in the molecular mechanisms of metastasis and EMT. J Mammary Gland Biol Neoplasia. 12:99–102. 2007. View Article : Google Scholar

5 

Moreno-Bueno G, Portillo F and Cano A: Transcriptional regulation of cell polarity in EMT and cancer. Oncogene. 27:6958–6969. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Yap AS, Brieher WM, Pruschy M and Gumbiner BM: Lateral clustering of the adhesive ectodomain: A fundamental determinant of cadherin function. Curr Biol. 7:308–315. 1997. View Article : Google Scholar : PubMed/NCBI

7 

Carneiro P, Figueiredo J, Bordeira-Carriço R, Fernandes MS, Carvalho J, Oliveira C and Seruca R: Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opin Ther Targets. 17:1187–1201. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Pal S, Ganguly KK and Chatterjee A: Extracellular matrix protein fibronectin induces matrix metalloproteinases in human prostate adenocarcinoma cells PC-3. Cell Commun Adhes. 20:105–114. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, Zhang H, Chen X, Yang Y and Liu G: miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One. 8:e701922013. View Article : Google Scholar

11 

Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, et al: N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 67:3106–3116. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Mandal A, Bhatia D and Bishayee A: Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats. Mol Cell Biochem. 384:239–250. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Nichols SA, Roberts BW, Richter DJ, Fairclough SR and King N: Origin of metazoan cadherin diversity and the antiquity of the classical cadherin/β-catenin complex. Proc Natl Acad Sci USA. 109:13046–13051. 2012. View Article : Google Scholar

14 

Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R, et al: SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5′-CACCT sequences in candidate target genes. J Biol Chem. 274:20489–20498. 1999. View Article : Google Scholar : PubMed/NCBI

15 

Katoh M and Katoh M: Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1α, POU/OCT, and NF-κB. Int J Oncol. 34:1737–1742. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Nam EH, Lee Y, Park YK, Lee JW and Kim S: ZEB2 upregulates integrin α5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis. 33:563–571. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Zhao C, Qiao Y, Jonsson P, Wang J, Xu L, Rouhi P, Sinha I, Cao Y, Williams C and Dahlman-Wright K: Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res. 74:3983–3994. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ and Yang J: Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71:245–254. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L and Yang J: Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 19:372–386. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Barrallo-Gimeno A and Nieto MA: The Snail genes as inducers of cell movement and survival: Implications in development and cancer. Development. 132:3151–3161. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Hemavathy K, Guru SC, Harris J, Chen JD and Ip YT: Human Slug is a repressor that localizes to sites of active transcription. Mol Cell Biol. 20:5087–5095. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM and Look AT: Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell. 123:641–653. 2005. View Article : Google Scholar : PubMed/NCBI

25 

O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R III, Le Beau MM, Earp HS and Liu ET: axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 11:5016–5031. 1991. View Article : Google Scholar : PubMed/NCBI

26 

Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, Pandey A and Cole PA: Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci USA. 103:9773–9778. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Hafizi S and Dahlbäck B: Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273:5231–5244. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Duprey P and Paulin D: What can be learned from intermediate filament gene regulation in the mouse embryo. Int J Dev Biol. 39:443–457. 1995.PubMed/NCBI

29 

Stewart M: Intermediate filament structure and assembly. Curr Opin Cell Biol. 5:3–11. 1993. View Article : Google Scholar : PubMed/NCBI

30 

Takeda K and Akira S: STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 11:199–207. 2000. View Article : Google Scholar : PubMed/NCBI

31 

Manabe R, Oh-e N and Sekiguchi K: Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem. 274:5919–5924. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Ohnishi T, Hiraga S, Izumoto S, Matsumura H, Kanemura Y, Arita N and Hayakawa T: Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: Clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis. 16:729–741. 1998. View Article : Google Scholar

33 

Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, Cronberg T, Isshiki A, Erickson HP and Fässler R: Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 7:324–330. 2001. View Article : Google Scholar : PubMed/NCBI

34 

Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S and Globus RK: Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci. 109:1369–1380. 1996.PubMed/NCBI

35 

Johansson S, Svineng G, Wennerberg K, Armulik A and Lohikangas L: Fibronectin-integrin interactions. Front Biosci. 2:d126–d146. 1997. View Article : Google Scholar : PubMed/NCBI

36 

Sottile J and Hocking DC: Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell. 13:3546–3559. 2002. View Article : Google Scholar : PubMed/NCBI

37 

Goerges AL and Nugent MA: pH regulates vascular endothelial growth factor binding to fibronectin: A mechanism for control of extracellular matrix storage and release. J Biol Chem. 279:2307–2315. 2004. View Article : Google Scholar

38 

Rao B, Lain S and Thompson AM: p53-Based cyclotherapy: Exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy. Br J Cancer. 109:2954–2958. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Ma X, Liu L, Nie W, Li Y, Zhang B, Zhang J and Zhou R: Prognostic role of caveolin in breast cancer: A meta-analysis. Breast. 22:462–469. 2013. View Article : Google Scholar : PubMed/NCBI

40 

Reed JC: Apoptosis mechanisms: Implications for cancer drug discovery. Oncology (Williston Park). 18(Suppl 10): 11–20. 2004.

41 

Cohen GM: Caspases: The executioners of apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI

42 

Thornberry NA: Caspases: Key mediators of apoptosis. Chem Biol. 5:R97–R103. 1998. View Article : Google Scholar : PubMed/NCBI

43 

Zheng TS, Hunot S, Kuida K and Flavell RA: Caspase knockouts: Matters of life and death. Cell Death Differ. 6:1043–1053. 1999. View Article : Google Scholar : PubMed/NCBI

44 

Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI

45 

Zhou P, Jiang W, Weghorst CM and Weinstein IB: Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 56:36–39. 1996.PubMed/NCBI

46 

Arnold A and Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 23:4215–4224. 2005. View Article : Google Scholar : PubMed/NCBI

47 

Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7:331–342. 1993. View Article : Google Scholar : PubMed/NCBI

48 

Lundberg AS and Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 18:753–761. 1998. View Article : Google Scholar : PubMed/NCBI

49 

Weinberg RA: The retinoblastoma protein and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI

50 

Malumbres M and Barbacid M: To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer. 1:222–231. 2001. View Article : Google Scholar

51 

Malumbres M and Barbacid M: Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell. 9:2–4. 2006. View Article : Google Scholar : PubMed/NCBI

52 

Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI

53 

Hayden MS and Ghosh S: Signaling to NF-kappaB. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI

54 

Calaf GM and Hei TK: Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis. 21:769–776. 2000. View Article : Google Scholar : PubMed/NCBI

55 

Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:6075–6086. 1990.PubMed/NCBI

56 

Calaf G, Russo J and Alvarado ME: Morphological phenotypes in neoplastic progression of benz(alpha)pyrene-treated breast epithelial cells. J Submicrosc Cytol Pathol. 32:535–545. 2000.

57 

Calaf G, Russo J, Tait L, Estrad S and Alvarado ME: Morphological phenotypes in neoplastic progression of human breast epithelial cells. J Submicrosc Cytol Pathol. 32:83–96. 2000.PubMed/NCBI

58 

Calaf G and Hei TK: Oncoprotein expression in human breast epithelial cells transformed by high-LET radiation. Int J Radiat Biol. 77:31–40. 2001. View Article : Google Scholar : PubMed/NCBI

59 

Calaf GM, Alvarado ME and Hei TK: Beta catenin is associated with breast cancer progression in vitro. Int J Oncol. 26:913–921. 2005.PubMed/NCBI

60 

Calaf GM, Alvarado ME and Hei TK: Oncoprotein expression and morphological phenotypes of human breast epithelial cells transformed by the c-Ha-ras oncogene. Oncol Rep. 14:885–893. 2005.PubMed/NCBI

61 

Rodrigues CO, Nerlick ST, White EL, Cleveland JL and King ML: A Myc-Slug (Snail2)/Twist regulatory circuit directs vascular development. Development. 135:1903–1911. 2008. View Article : Google Scholar : PubMed/NCBI

62 

Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, Knyazeva T, Barbieri V, Reindl M, Muigg A, et al: Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 14:130–138. 2008. View Article : Google Scholar : PubMed/NCBI

63 

Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI

64 

Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G and Ullrich A: AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 68:1905–1915. 2008. View Article : Google Scholar : PubMed/NCBI

65 

Wang S, Yu S, Shi W, Ge L, Yu X, Fan J and Zhang J: Curcumin inhibits the migration and invasion of mouse hepatoma Hca-F cells through down-regulating caveolin-1 expression and epidermal growth factor receptor signaling. IUBMB Life. 63:775–782. 2011. View Article : Google Scholar

66 

Sun LN, Chen ZX, Liu XC, Liu HY, Guan GJ and Liu G: Curcumin ameliorates epithelial-to-mesenchymal transition of podocytes in vivo and in vitro via regulating caveolin-1. Biomed Pharmacother. 68:1079–1088. 2014. View Article : Google Scholar : PubMed/NCBI

67 

Limtrakul P: Curcumin as chemosensitizer. Adv Exp Med Biol. 595:269–300. 2007. View Article : Google Scholar : PubMed/NCBI

68 

Reuter S, Eifes S, Dicato M, Aggarwal BB and Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol. 76:1340–1351. 2008. View Article : Google Scholar : PubMed/NCBI

69 

Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN and Kuttan R: Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 94:79–83. 1995. View Article : Google Scholar : PubMed/NCBI

70 

Choudhuri T, Pal S, Das T and Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 280:20059–20068. 2005. View Article : Google Scholar : PubMed/NCBI

71 

Salim LZ, Mohan S, Othman R, Abdelwahab SI, Kamalidehghan B, Sheikh BY and Ibrahim MY: Thymoquinone induces mitochondria-mediated apoptosis in acute lymphoblastic leukaemia in vitro. Molecules. 18:11219–11240. 2013. View Article : Google Scholar : PubMed/NCBI

72 

Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, et al: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 424:516–523. 2003. View Article : Google Scholar : PubMed/NCBI

73 

Pekar O, Molotski N, Savion S, Fein A, Toder V and Torchinsky A: p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-kappaB DNA binding. Reproduction. 134:379–388. 2007. View Article : Google Scholar : PubMed/NCBI

74 

Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene. 22:9030–9040. 2003. View Article : Google Scholar : PubMed/NCBI

75 

Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005. View Article : Google Scholar : PubMed/NCBI

76 

Calaf GM, Echiburú-Chau C, Roy D, Chai Y, Wen G and Balajee AS: Protective role of curcumin in oxidative stress of breast cells. Oncol Rep. 26:1029–1035. 2011.PubMed/NCBI

77 

Huang T, Chen Z and Fang L: Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells. Oncol Rep. 29:117–124. 2013.

Related Articles

Journal Cover

June-2016
Volume 48 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gallardo M and Calaf GM: Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen. Int J Oncol 48: 2534-2542, 2016.
APA
Gallardo, M., & Calaf, G.M. (2016). Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen. International Journal of Oncology, 48, 2534-2542. https://doi.org/10.3892/ijo.2016.3477
MLA
Gallardo, M., Calaf, G. M."Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen". International Journal of Oncology 48.6 (2016): 2534-2542.
Chicago
Gallardo, M., Calaf, G. M."Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen". International Journal of Oncology 48, no. 6 (2016): 2534-2542. https://doi.org/10.3892/ijo.2016.3477